Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

Raymond Schuch; Babar Khalid Khan; Assaf Raz; Jimmy A. Rotolo; Michael Wittekind

doi:10.1128/AAC.02666-16

Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

Raymond Schuch, Babar Khalid Khan, Assaf Raz, Jimmy A. Rotolo, Michael Wittekind

Biological, Environmental Sciences and Engineering

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Abstract

Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC90) value of

Original language	English (US)
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	7
DOIs	https://doi.org/10.1128/AAC.02666-16
State	Published - May 1 2017

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: The work of Raymond Schuch, Babar K. Khan, Jimmy A. Rotolo, and Michael Wittekind was supported by the ContraFect Corporation. The work of Assaf Raz was supported by U.S. Public Health Service grant AI11822 (to Vincent A. Fischetti).

Access to Document

10.1128/AAC.02666-16

https://repository.kaust.edu.sa/bitstream/10754/625401/1/Antimicrob.%20Agents%20Chemother.-2017-Schuch-.pdf

Cite this

@article{5bbdb15d9b62449fa6424f9c136d89a7,

title = "Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent",

abstract = "Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC90) value of",

author = "Raymond Schuch and Khan, {Babar Khalid} and Assaf Raz and Rotolo, {Jimmy A.} and Michael Wittekind",

note = "KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: The work of Raymond Schuch, Babar K. Khan, Jimmy A. Rotolo, and Michael Wittekind was supported by the ContraFect Corporation. The work of Assaf Raz was supported by U.S. Public Health Service grant AI11822 (to Vincent A. Fischetti).",

year = "2017",

month = may,

day = "1",

doi = "10.1128/AAC.02666-16",

language = "English (US)",

volume = "61",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

AU - Schuch, Raymond

AU - Khan, Babar Khalid

AU - Raz, Assaf

AU - Rotolo, Jimmy A.

AU - Wittekind, Michael

N1 - KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: The work of Raymond Schuch, Babar K. Khan, Jimmy A. Rotolo, and Michael Wittekind was supported by the ContraFect Corporation. The work of Assaf Raz was supported by U.S. Public Health Service grant AI11822 (to Vincent A. Fischetti).

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC90) value of

AB - Biofilms pose a unique therapeutic challenge because of the antibiotic tolerance of constituent bacteria. Treatments for biofilm-based infections represent a major unmet medical need, requiring novel agents to eradicate mature biofilms. Our objective was to evaluate bacteriophage lysin CF-301 as a new agent to target Staphylococcus aureus biofilms. We used minimum biofilm-eradicating concentration (MBEC) assays on 95 S. aureus strains to obtain a 90% MBEC (MBEC90) value of

UR - http://hdl.handle.net/10754/625401

UR - http://aac.asm.org/content/61/7/e02666-16

UR - http://www.scopus.com/inward/record.url?scp=85022039620&partnerID=8YFLogxK

U2 - 10.1128/AAC.02666-16

DO - 10.1128/AAC.02666-16

M3 - Article

SN - 0066-4804

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

ER -

Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this